Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial
Cancer Immunology, Immunotherapy · 20.11.2025 · 74 (12)
DOI: 10.1007/s00262-025-04237-3 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 20.11.2025. Verfasst von Wen Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Hope Run Special Fund of Cancer Foundation of China, Beijing Natural Science Foundation, Major Project/Translational research project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
- Medical Department, 3D Medicines Inc., Shanghai, 201114, China.
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. aiping_z…
Förderung
- Beijing Hope Run Special Fund of Cancer Foundation of China
- Beijing Natural Science Foundation
- Major Project/Translational research project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences
- CAMS Innovation Fund for Medical Sciences (CIFMS)
Zitieren
APA
Zhang, W., Gong, C. F., Huang, J. L., Liu, T. Y., Sun, Y. K., Jiang, Z. C., Qu, W., Yang, L., Xin, Y., Zhao, F. L., Bai, Y. Z., & Zhou, A. P. (2025). Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial. Cancer Immunology, Immunotherapy, 74(12). https://doi.org/10.1007/s00262-025-04237-3
Vancouver
Zhang W, Gong CF, Huang JL, Liu TY, Sun YK, Jiang ZC, et al. Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial. Cancer Immunology, Immunotherapy. 2025;74(12). doi:10.1007/s00262-025-04237-3
BibTeX
@article{Zhang2025,
author = {Zhang, Wen and Gong, Cai-Feng and Huang, Jing-Long and Liu, Tian-Yi and Sun, Yong-Kun and Jiang, Zhi-Chao and Qu, Wang and Yang, Lin and Xin, Ying and Zhao, Fei-Long and Bai, Yue-Zong and Zhou, Ai-Ping},
title = {Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {12},
doi = {10.1007/s00262-025-04237-3}
}
EUVIMED